About Nizubaglustat
Nizubaglustat About Nizubaglustat Nizubaglustat (AZ-3102): a new investigational drug for GM2 gangliosidosis and other rare diseases
Short summary
Nizubaglustat (AZ-3102) is an experimental drug administered by mouth that is currently being investigated as a possible treatment for some rare inherited diseases affecting the nervous system. These also include GM2 gangliosidosis, a disease that includes Tay Sachs disease and Sandhoff's disease. The drug is not yet approved for general use, and its efficacy and safety are now being verified in international phase III clinical trials. [clinicaltrials.gov], [azafaros.com], [azafaros.com]
What is nizubaglustat?
Nizubaglustat is a small molecule developed by Azafaros for the treatment of rare lysosomal storage diseases with neurological impairment. The advantage of this substance is that it is designed to reach the brain and central nervous system after administration, which is very important in GM2 gangliosidosis. [azafaros.com], [azafaros.com], [pmc.ncbi.nlm.nih.gov]
How should the drug work?
In GM2 gangliosidosis, substances accumulate in cells, especially in nerve tissue, that the body cannot properly break. Nizubaglustat is developed to affect the metabolism of certain fatty substances and reduce their harmful accumulation in cells. This could help slow down the damage to the nervous system and the course of the disease. [azafaros.com], [inpda.org], [pmc.ncbi.nlm.nih.gov]
According to current expert information, nizubaglustat has a dual mechanism of action – it acts on two important enzymes involved in glycolipid metabolism. It is this combined effect that is one of the reasons why this substance is considered a promising candidate for the treatment of neurological forms of lysosomal storage disorders. [pmc.ncbi.nlm.nih.gov], [inpda.org]
What diseases is it being investigated for?
Nizubaglustat is currently being developed for three serious rare diseases:
• Niemann–Pick disease type C (NPC), in which the processing and transport of fats in cells is impaired. [clinicaltrials.gov], [azafaros.com]
• GM1 gangliosidosis, a genetic disease associated with ganglioside accumulation. [clinicaltrials.gov], [azafaros.com]
• GM2 gangliosidosis, which includes Tay Sachs disease and Sandhoff's disease. [clinicaltrials.gov], [azafaros.com]
It is important for the community of families living with Tay Sachs or Sandhoff's disease that this is a drug that is being developed directly for GM2 gangliosidosis. [clinicaltrials.gov], [azafaros.com]
At what stage of development is the drug?
According to the ClinicalTrials.gov registry, a global Phase III clinical trial called NAVIGATE (registration number NCT07054515) is currently underway. This is a randomised, double-blind, placebo-controlled trial that monitors the safety and efficacy of oral nizubaglustat in patients with late infantile and juvenile forms of these diseases. The study includes patients from 4 years of age and is being conducted at multiple sites in several regions of the world. [clinicaltrials.gov], [azafaros.com]
At the same time, Azafaros states that these studies are intended to provide key data needed for possible future approval of treatments. However, this means that the research is still ongoing and it is not yet certain what the final result will be. [azafaros.com], [azafaros.com]
What do the results show so far?
In 2026, Azafaros reported the publication of data from the RAINBOW phase II study, according to which nizubaglustat was safe and well tolerated, and at the same time there were encouraging signs of action, for example in slowing the progression of the disease and reducing the seizure burden in some patients with GM2 gangliosidosis and NPC. However, it is important to emphasize that these results now need to be confirmed in larger phase III studies [azafaros.com], [azafaros.com]
Does the drug already have any special regulatory status?
Yes. Nizubaglustat has been designated Orphan Drug Designation in some indications and Rare Pediatric Disease Designation in the USA. These labels can support and accelerate the development of treatments, but they do not mean that the drug is already approved and widely available to patients. [azafaros.com], [ema.europa.eu], [azafaros.com]
What is important to know for patients and families
Nizubaglustat is a promising direction of research today, but it is still an investigational treatment that is undergoing clinical trials. It is important for patients and their loved ones to follow verified information, to distinguish between "promising developments" and "approved treatments", and to consult everything with the attending specialist if they are interested in clinical trials. At the moment, it is therefore most accurate to say that nizubaglustat is a promising candidate, whose real benefit is currently being verified. [clinicaltrials.gov], [azafaros.com], [ema.europa.eu]